The introduction of disease-modifying monoclonal antibodies and genetically engineered biologic products, such as the TNF antagonist infliximab for RA and Crohn’s disease (Kornbluth, 1998; Lipsky et al., 2000), represented a major advance in the treatment of autoimmunity, because these agents generally act with greater specificity and lower toxicity than corticosteroids and other general immunosuppressive agents (St Clair, 2009). Here, TNF is linked to rheumatoid arthritis.